The U.S. Market for Rx to OTC Switches, 6th Edition

NEW YORK, April 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The U.S. Market for Rx to OTC Switches, 6th Edition
http://www.reportlinker.com/p01095492/The-US-Market-for-Rx-to-OTC-Switches-6th-Edition- .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once only available by prescription. This report represents the six time that Kalorama Information has analyzed the market for drugs with switched ingredients in detail. The market is fueled by several factors including an aging population; steady to increased incidences of conditions and diseases; new drug classes switched to OTC; product demand; economic conditions and several other factors.

The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available. These include:

• Allergy, Cough, Cold, and Sinus Products

• Analgesics, NSAIDs, and Pain Treatments

• Anti-Infectives

• Gastrointestinal Drugs

• Hair Loss Products

• Hormones

• Oral Care

• Rectal Ointments

• Sleep-aids

• Smoking Cessation

• Weight Loss

In addition to the areas with switches in place, Kalorama Information has identified other areas which may be open to Rx-to-OTC switches in the future. These include:

• Blood Products

• BPH Treatments

• Cholesterol-reducing Drugs

• Hormone Replacement Therapies

• Migraine Treatments

• Osteoporosis Treatments

• Overactive Bladder

• Sexual Dysfunction/ Erectile Dysfunction

The report covers OTC drugs that were once only available by prescription due to either the active ingredient or dosage of the drug. Current and historical revenues for product segments include both the switched brands and OTC drugs containing switched ingredients. Forecasted data includes current products and forecasted switches which are outlined in the report.

The report includes statistical information for conditions and diseases affecting the U.S. population, including detail discussions, tables and figures. Each segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. In addition to above-mentioned information, the report includes current issues and trends affecting the industry and identifies trends that may arise in the future.

All product areas contribute to the growth and development of the OTC market; however, new product development and additional regulatory review and approval of new OTC drug classifications, specifically in areas such as allergy treatments, cholesterol-reducing drugs, urinary disorders treatments and hormones treatments are expected to make the most impact.

There are several companies that compete heavily in this market and use the Rx-to-OTC switch as a major part of their life-cycle management arsenal. Companies involved in the Rx-to-OTC switched market include brand, generic, and private label manufacturers. Competition will likely continue to be moderate in the OTC market, especially with the patent expiration of key products nearing. Consolidation remains a major factor in this market. Most major players have made a significant acquisition or formed a strategic alliance to increase revenues and drive growth. Product innovation, line extensions and strong promotional support are a few of the top strategies for growth in this industry.

Leading competitors offering key brand products are provided in this report. These companies include:

• Bayer Healthcare

• Boehringer Ingelheim

• GlaxoSmithKline

• Insight Pharmaceuticals

• Johnson & Johnson

• Merck

• Novartis

• Pfizer

• Prestige Brands

• Procter & Gamble

• Reckitt Benckiser

• Sanofi (Chattem)

• TEVA

 

 

CHAPTER ONE: EXECUTIVE SUMMARY

Scope and Methodology

Size and Growth of the Market

Issues and Trends Affecting the Rx-to-OTC Switches Market

Leading Competitors

CHAPTER TWO: INTRODUCTION

Overview of the Over-the-Counter Market

Development of the Rx-to-OTC Drug Market

Rx-to-OTC Industry

Economic Indicators

The FDA and Rx-to-OTC Switches

CHAPTER THREE: ALLERGY, COUGH, COLD, AND SINUS PRODUCTS

Overview

Antihistamines

Decongestants

Cough Preparations

Mast Cell Stabilizers

Ophthalmic Preparations

Description of Conditions

Allergic Rhinitis

Common Cold

Sinusitis

Hives

Ocular Allergies

Product Analysis

Switched Products

Antihistamines

Decongestants

Cough Preparations

Mast Cell Stabilizers

Ophthalmic Preparations

Prescription Products with Anticipated OTC Approvals

Xyzal

Clarinex

Astelin Nasal Spray

Atrovent Nasal Spray

Flonase

Nasacort AQ

Rhinocort

Nasonex

Beconase AQ

Market Analysis

Market Size and Forecast

Competitive Analysis

CHAPTER FOUR: ANALGESICS AND OTHER PAIN RELIEVERS

Overview

Analgesics

Nonsteroidal Anti-inflammatory Drugs

Topical Pain Relievers and Other Similar Products

Description of Conditions

Pain

Inflammation

Product Analysis

Switched Ingredients

Antipruritic

Internal analgesic/antipyretic

Oral anesthetic

Prescription Products with Anticipated OTC Approvals

Nonsteroidal anti-inflammatory drugs

Voltaren (diclofenac)

Diflunisal

Etodolac

Nabumetone

Feldene (piroxicam)

Migraine treatments

Axert

Imitrex

Maxalt

Zomig

Other Migraine Treatments

Market Analysis

Market Size and Forecast

Competitive Analysis

CHAPTER FIVE: ANTI-INFECTIVES

Overview

Antibiotics

Antifungals

Antivirals

Antiparasitics

Description of Conditions

Vaginal Infections

Athlete's Foot

Jock Itch

Ringworm

Dandruff

Scabies and Pediculosis

Pinworm

Fungal Nail Infections

Product Analysis

Switched Ingredients

Antifungals

Anthelmintics

Antimicrobials

Pediculicides

Prescription Products with Anticipated OTC Approvals

Antivirals

Zovirax

Valtrex

Denavir

Famvir

Influenza Antivirals

Antibiotics

Antifungals

Market Analysis

Market Size and Forecast

Competitive Analysis

CHAPTER SIX: GASTROINTESTINAL DRUGS

Overview

Description of Conditions

Nausea

Diarrhea

Constipation

Heartburn

Acid reflux

Product Analysis

Switched Ingredients

Histamine H2 Inhibitors

Proton Pump Inhibitors

Antidiarrheals

Laxatives

Antiemetics

Prescription Products with Anticipated OTC Approvals

Proton Pump Inhibitors

Nexium

Protonix

Aciphex

Mucosal Protectants

Antiemetics

Market and Competitive Analysis

Market Size and Forecast

Competitive Analysis

CHAPTER SEVEN: SMOKING CESSATION PRODUCTS

Overview

Description of Conditions

Lung Cancer and Tobacco Use

Product Analysis

Switched Ingredients

Prescription Products with Anticipated OTC Approvals

Nicotrol

Chantix

Market Analysis

Market Size and Forecast

Competitive Analysis

CHAPTER EIGHT: OTHER DRUG CLASSIFICATIONS

Overview

Contraceptives

Dental Rinses and Fluorides

Hair Growth Products

Rectal Ointments

Sleep Aids

Weight Management

Description of Conditions

Pregnancy

Global Birth Rates

Abortion Rates

Contraceptive Use

Dental carries

Hereditary Hair Loss

Hemorrhoids

Sleeplessness

Obesity

Conditions with Possible Future OTC Treatments

Acne Vulgaris

Benign Prostate Hypertrophy (BPH)

Elevated Cholesterol

Erectile Dysfunction

Menopause and Hormone Replacement

Menorrhagia

Osteoporosis

Urinary Incontinence/Overactive Bladder

Product Analysis

Switched Ingredients

Contraceptives

Dental rinses and fluoride

Hair growth

Rectal ointments

Sleep aids

Weight Management

Prescription Products with Anticipated OTC Approvals

Acne Treatments

Cholesterol-reducing Drugs (antilipidemics)

Blood Products

BPH

Erectile Dysfunction

Hair Loss Treatment

Hormone-Replacement Therapies (HRT)

Osteoporosis Treatments

Overactive Bladder

Sleep Aids

Market Analysis

Current Market Segments

Short-Term New Product Segment Development; 2013-2017

Product segments with short-term potential include:

Antilipidemics

BPH Treatments

Hormone Replacement Therapy and Osteoporosis Treatments

Overactive Bladder Treatments

New Product Segments; Post 2017

Sexual Dysfunction

Competitive Analysis

CHAPTER NINE: TOTAL MARKET SUMMARY

Overview

Total market Size and Forecast

Competitive Analysis

CHAPTER TEN: ISSUES AND TRENDS AFFECTING THE RX-TO-OTC MARKET

Introduction

Regulatory Authorities

Additional Drug Access

Using Technology or Pharmacies for Nonprescription Drug Access

Physicians and Increasing Nonprescription Drug Access

Impact on the Consumer

Online Resources for Health Information

OTC Availability

Insurance Issues and Reimbursement for OTC Drugs

Health Insurance Trends in the United States

Healthcare Flexible Spending Accounts, Health Savings Accounts and OTC Medicines

Changing the Pharmacist's Role

Impact on the Prescription Drug Manufacturer

Strategies for Continued Product Growth

Mergers and Acquisitions

Procter & Gamble and Teva Pharmaceutical Industries

Sanofi and Chattem Consumer

Schering-Plough and Merck & Co

Wyeth and Pfizer

Reckitt Benckiser and Adams Respiratory Therapeutics

Bristol-Myers Squibb and Novartis AG

Johnson & Johnson and Pfizer

Reckitt Benckiser and Boots Healthcare

Bayer and Roche

Strategies in Switching

Dual Status Switching

Generic Competition

Direct-to-Consumer Advertising

Patent Expiration

International Trends in Rx-to-OTC Switches

Consumers around the World

Streamlined Access to OTC Drug Products in Canada

Prescription vs Over-the-Counter Industry

World Health, Demographics and Life Expectancy

Life Expectancy

Birth Rates

CHAPTER ELEVEN: COMPANY PROFILES

Introduction

Bayer Healthcare

Boehringer Ingelheim

GlaxoSmithKline

Insight Pharmaceuticals

Johnson & Johnson

Merck & Co

Novartis

Pfizer

Prestige Brands

Procter & Gamble

Reckitt Benckiser

Sanofi/Chattem

TEVA

APPENDIX: COMPANY DIRECTORY

To order this report:
: The U.S. Market for Rx to OTC Switches, 6th Edition



__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker